Validate the binding strength of individual T cell peptide epitope candidates in order to judge their immunogenic potential.
Peptide Epitope Validation
Accurately determine half maximal inhibitory concentrations (IC50), representative of the binding affinity where your unlabeled test peptide competes with a labeled reference peptide for HLA binding from a wide range of alleles.
How it Works
Provide a synthetic peptide
Select peptides from previous screening results originally derived from target source proteins in cancer and infectious disease applications, from putative epitopes originated from predictive algorithms or select altered or mutated peptides from viral variance studies or tumor-specific mutations.
Select an HLA molecule
Select from a broad representation of HLA alleles to be applied in our peptide binding assays. Our service is very flexible, ensures expedited results, and employs highly-purified single specificity soluble HLA proteins from mammalian cell lines to guarantee outstanding performance in accuracy, sensitivity and reproducibility.
Receive the data
Inhibitory concentrations are determined by incubating sHLA with a labeled reference peptide in the presence of different concentrations of competitor peptide. We deliver a calculated logIC50 value as measure of the effectiveness of the competing test peptide. Affinity categories will prioritize your logIC50 values into high, medium, or low affinity binders.
Validate Screening Hits
Confirm the validity of your screening hits and properly prioritize potential T-cell epitopes according to their HLA affinity. Successful elimination of false positive or negative screening results will increase confidence and reduce risks working with your target source proteins from cancer or infectious diseases applications.
Validation of Predicted Peptides
Our HLA binding assays do what prediction tools cannot. They confirm the physical binding characteristics of actual peptides. Directly measure the binding strength of your predicted peptides, allow proper prioritization and successfully eliminate false positive or negative results generated by computer algorithms.
Validate Mutational Variations
Validate neo-epitope candidates from tumor-specific mutations for their increased or decreased binding or peptides covering viral escape mutations measuring the loss of reactivity against the wild-type to determine a potential sequential accumulation of CTL escape in patients during disease progression.
Explore whether target modulation will improve your binding potency. Identify vaccine candidates not providing the desired immune response levels and test their redesign by easily alter potential anchor positions for improved binding and quickly assess and compare the results of those modifications.
Talk to an expert today
Want to know more about our Validation Systems?
If you’re still wondering if our services are the right technology to take you to the next level and are looking for some clarity, reach out to our experts and someone from our team will get back to you in no time.
Expert advice, whenever you need it!
Related Products & Services
Select from a pool of over 65 HLA-B alleles to drive your immunological research to identify antibody immune responses or visualize antigen-specific immune cells.
Discover a selection of over 20 HLA-C alleles, the dominant ligand for KIR on NK cells for your immunological research.